Valion Bio (VIBO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
5 Jun, 2026Opening remarks and agenda
Meeting opened by CEO, marking the first annual meeting under the new company name and Nasdaq ticker VBIO.
Emphasis on shareholder engagement as foundational to value creation.
Introduction of board members and key executives in attendance.
Meeting procedures, voting eligibility, and quorum established.
Financial performance review
Over $140 million invested in lead drug development, with more than 300 patients dosed.
2025 described as a year of fundamental transformation, with 2026 focused on execution.
Board and executive committee updates
Dean Zikria nominated and elected as Class 2 Director for a three-year term.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Valion Bio
- Shareholders approved board authority for a reverse stock split and potential meeting adjournment.VIBO
EGM 2026 - Net loss widened on higher R&D and CDMO costs, with urgent need for new funding and Nasdaq compliance risks.VIBOQ2 2026
- Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.VIBOProxy filing
- Biopharma pivots to Entolimod, raising up to $13.7M via flexible share/warrant offering.VIBORegistration filing
- Shareholders will vote on a reverse stock split to maintain Nasdaq compliance and potential adjournment authority.VIBOProxy filing
- Q1 2026 saw higher expenses, net loss, and liquidity risks amid strategic transformation.VIBOQ1 2026
- Shareholders will vote on director election, equity plan, auditor, and major share issuance approvals.VIBOProxy filing
- Board recommends approval of director, equity plan, auditor, and major share issuance proposals.VIBOProxy filing
- Late-stage immune therapies advance toward approval, with Entolimod targeting ARS and neutropenia.VIBOEmerging Growth Conference 91